Currently, immune checkpoints within the TME have been identified as potential therapeutic targets, but the role of PD-1/PD-L1 in the TME remains largely undetermined for ICC [26]. This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.